Previous 10 | Next 10 |
PDUFA date set for March 18, 2024 OTL-200 would be the first and only treatment in the U.S. for early-onset MLD Previously published data demonstrated administration of one-time gene therapy enables sustained preservation of motor function and cognitive development BOSTON ...
Administration of one-time gene therapy resulted in statistically significant improvement in severe motor impairment-free survival with up to 12 years of follow-up (median 6.76 years) Composite primary endpoint used in analysis was developed through discussions with the U.S. Food and Dr...
2023-08-03 13:26:16 ET Orchard Therapeutics plc (ORTX) Q2 2023 Earnings Conference Call August 03, 2023, 08:30 AM ET Company Participants Bobby Gaspar - Chief Executive Officer Frank Thomas - President and COO Braden Parker - Chief Commercial Officer Confer...
2023-08-03 08:44:39 ET Orchard Therapeutics press release ( NASDAQ: ORTX ): Q2 GAAP EPS of -$0.07 beats by $0.55 . Revenue of $7.3M (+67.0% Y/Y) beats by $0.81M . The company expects its cash used to fund operations in 2023 to decline as compared to 2022 due ...
Reported $6.6M in Q2’23 Libmeldy net sales, representing the highest quarter to date $34.0M of additional capital from second closing of strategic financing extends runway to mid-2025 Four MLD patients identified from ~150,000 newborns screened in prospective studies sugg...
2023-08-02 16:08:29 ET Orchard Therapeutics ( NASDAQ: ORTX ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.62 (-55.0% Y/Y) and the consensus Revenue Estimate is $6.49M (+48.5% Y/Y). Over the ...
BOSTON and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, expresses its strong appreciation for the passage of the Newborn Metabolic Screening Act in Illinois, also known as SB67. The law, anticipated to go into effect in January 2024,...
2023-07-29 00:49:07 ET Summary ORTX has been a terrible destroyer of investor value. Today, it has an upcoming BLA and a decent cash runway. There are various risks here, but if things work out, there may be some upside here. I have been covering Orchard Therapeutics ( ...
BOSTON and LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the company will host a conference call and live webcast on Thursday, August 3, 2023, at 8:00 a.m. EDT to review business updates and its second quarter 202...
2023-06-26 14:29:18 ET Orchard Therapeutics ( NASDAQ: ORTX ) said that it has closed on a second $34M financing as part of a larger agreement that could garner the company up to $188M if certain regulatory milestones are met. The second financing included the issuance of 4.25M A...
News, Short Squeeze, Breakout and More Instantly...
Orchard Therapeutics plc Company Name:
ORTX Stock Symbol:
NASDAQ Market:
Orchard Therapeutics plc Website:
TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe, today announced that Bobby Gaspar, M.D., Ph.D., co-founder and chief executive officer, ...
Crescent Energy Company Class A (CRGY) is expected to report $0.21 for Q4 2023 ThredUp Inc. (TDUP) is expected to report $-0.13 for Q4 2023 Wright Investors` Service Holdings Inc (IWSH) is expected to report for Q4 2023 Bridgford Foods Corporation (BRID) is expected to report for Q1 2...
Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells HURCULES study to enroll 40 patients at clinical sites across the U.S....